Multiple Sclerosis: Brain Effects and Cognitive Changes

Multiple sclerosis (MS): When the Immune System Gets Its Signals Crossed

Multiple sclerosis (MS) is a chronic neurological disease in which an abnormal immune response damages myelin, the protective covering around nerve fibres in the brain and spinal cord. This can disrupt communication between different parts of the nervous system, producing symptoms such as vision changes, numbness, weakness, balance problems, fatigue and, in some people, changes in memory, attention or processing speed. MS varies considerably between individuals, and modern diagnosis, disease-modifying treatments and rehabilitation can help reduce disease activity and manage its effects.

What Happens When the Brain’s Wiring Starts Misfiring?

Imagine the brain and spinal cord as an enormous communication network. Billions of nerve fibres constantly carry electrical messages that allow a person to see, walk, remember, concentrate, speak and respond to the world. For these messages to travel efficiently, many nerve fibres are wrapped in myelin, an insulating material that helps signals move rapidly. In multiple sclerosis, the immune system mistakenly attacks components of the central nervous system, particularly myelin. The resulting inflammation and damage can interrupt communication between the brain, spinal cord and the rest of the body. MS can also damage axons and nerve cells themselves, which helps explain why the condition can affect both physical and cognitive function.

The result is not one predictable pattern. One person may experience an episode of blurred vision, another may notice numbness or balance problems, while someone else may primarily struggle with fatigue or slower thinking. Symptoms can appear, improve and return, or gradually become more persistent depending on the disease course. That variability is one reason MS is often described as a disease with many faces.

What Happens in Multiple Sclerosis?

The central problem in MS is immune-mediated damage within the central nervous system. When myelin is damaged, nerve signals may slow down, become distorted or fail to reach their destination efficiently. Areas of damage can form scar-like lesions called sclerosis or plaques, which are often visible on MRI scans. MS can also affect axons and grey matter, meaning that the disease is not simply a disorder of the myelin sheath.

A useful way to picture this is to think of a high-speed electrical cable. Myelin acts somewhat like insulation around the cable. If that insulation becomes damaged, communication may become slower or unreliable. In MS, the situation is more complex because inflammation and direct injury to nerve structures can also contribute to lasting neurological changes.

What Causes MS?

There is no single cause of multiple sclerosis. Current evidence points to an interaction between immune, genetic and environmental factors rather than one trigger.
Several factors have been associated with MS risk:

• Epstein-Barr virus (EBV): EBV is the infection most consistently linked with later MS risk, although infection alone does not mean someone will develop MS.
• Genetic susceptibility: Having a close relative with MS increases risk, but MS is not considered a straightforward inherited disease.
• Sex: MS is more common in women than men.
• Environmental influences: Factors such as smoking, vitamin-D-related biology and other environmental exposures are being investigated.
• Immune-system differences: Multiple genetic variants associated with MS are involved in immune regulation.

Importantly, these are risk factors, not predictions. Having one does not mean a person will develop MS.

Types and Patterns of MS

MS does not follow one universal trajectory. Current terminology emphasizes whether disease is relapsing, progressive or active, rather than assuming every person follows the same sequence. The major clinical courses include:

• Clinically isolated syndrome (CIS): A first neurological episode that may or may not eventually meet criteria for MS.
• Relapsing-remitting MS (RRMS): Episodes of new or worsening symptoms are followed by periods of partial or substantial recovery. Most people are initially diagnosed with this form.
• Secondary-progressive MS (SPMS): Disability gradually accumulates after an earlier relapsing course, although some people continue to experience relapses.
• Primary-progressive MS (PPMS): Neurological function gradually worsens from the beginning rather than following a clear relapse-remission pattern.
• Radiologically isolated syndrome (RIS): MRI findings suggestive of MS occur without typical clinical symptoms; some people subsequently develop neurological symptoms.

Signs and Symptoms: Why MS Can Look So Different

Because lesions can occur in different parts of the brain and spinal cord, symptoms vary according to where the nervous system has been affected. Common manifestations include:

• Blurred or reduced vision, sometimes associated with optic neuritis
• Double vision
• Numbness or tingling
• Muscle weakness or stiffness
• Spasms
• Balance and coordination difficulties
• Dizziness
• Walking difficulties
• Bladder or bowel problems
• Fatigue
• Pain
• Mood changes
• Problems with attention, memory, multitasking or processing speed

<p.Heat, fever and infections can temporarily make existing symptoms feel worse in some people. This does not necessarily mean that new permanent disease damage has occurred.

The Cognitive Side of MS

MS is often associated with visible physical symptoms, but the cognitive effects deserve equal attention. Cognitive changes can involve:

• Processing speed: needing more time to understand or respond to information
• Attention: difficulty maintaining concentration, particularly when distractions are present
• Working memory: difficulty holding information in mind while using it
• Learning and recall: needing more repetition to retain new information
• Executive function: challenges with planning, multitasking or switching between activities

These changes do not mean that a person’s intelligence has disappeared. Instead, MS can affect how efficiently the brain processes information.

Fatigue, poor sleep, depression, pain and medication effects can also influence cognitive performance, making it important to consider the whole picture rather than attributing every concentration problem directly to MS. NINDS notes that cognitive changes can occur alongside physical symptoms or develop gradually.

A Real-World Clinical Perspective: HERCULES

A particularly important recent example comes from the Phase 3 HERCULES trial, which focused on people with non-relapsing secondary-progressive MS: a group for whom disability can continue to accumulate even when obvious relapses have become less frequent.

The study enrolled 1,131 participants and compared the investigational BTK inhibitor Tolebrutinib with placebo. Participants had secondary-progressive MS, evidence of disability progression and no recent clinical relapses. The trial was designed to examine whether treatment could delay confirmed disability progression.

The results, published in The New England Journal of Medicine in 2025, found that Tolebrutinib reduced the risk of six-month confirmed disability progression by about 31% compared with placebo. The finding is important because it targeted progression occurring outside obvious relapses. However, the treatment also produced safety concerns, particularly liver-enzyme elevations, demonstrating why promising clinical findings must always be considered alongside risks.

How Is Multiple Sclerosis Diagnosed?

There is no single test that confirms MS. Diagnosis involves combining the person’s history and neurological examination with evidence from investigations while excluding conditions that can produce similar symptoms. Doctors may use:

• MRI of the brain and spinal cord to identify characteristic lesions
• Lumbar puncture to examine cerebrospinal fluid for evidence of inflammation
• Evoked-potential testing to measure how quickly the nervous system responds to stimulation
• Optical or visual testing, including assessments of the optic nerve where appropriate
• Blood tests and other investigations to help exclude alternative diagnoses

MRI has become particularly important because it can reveal lesions that may not have produced noticeable symptoms.

Treatment and Management

There is currently no cure for MS, but treatment has changed dramatically. Management generally has several goals: reduce inflammatory disease activity, manage relapses when appropriate, slow disability accumulation where possible and address symptoms that interfere with daily life.

Disease-modifying therapies work through different mechanisms to reduce immune-mediated disease activity. The appropriate treatment depends on factors such as the MS type, disease activity, MRI findings, previous treatment and individual circumstances. These decisions require specialist medical assessment rather than a one-size-fits-all approach.  Relapses may sometimes be treated with corticosteroids, while symptoms such as fatigue, spasticity, pain, bladder problems, mobility difficulties and mood changes can require separate management strategies. Rehabilitation is often an important part of long-term care.

Recovery and Rehabilitation

Recovery from an MS episode can vary considerably. Some symptoms improve substantially, while others may persist. Rehabilitation aims to help a person regain function, compensate for limitations and remain as independent as possible. Depending on individual needs, rehabilitation may involve:

• Physiotherapy for strength, balance, mobility and movement
• Occupational therapy for daily activities, energy conservation and adaptations
• Speech and language therapy when communication or swallowing is affected
• Cognitive rehabilitation for memory, attention, processing speed and executive function
• Psychological support for emotional and behavioural challenges

The goal is not simply to treat a lesion on an MRI. It is to help the person function better in everyday life.

Neuroplasticity and Brain Adaptation

The brain is not entirely passive in the face of neurological damage. It can reorganize how certain functions are performed, recruit alternative networks and adapt to changes in neural pathways. This capacity is broadly known as neuroplasticity. In MS, rehabilitation may take advantage of this adaptability by repeatedly practising cognitive, motor or functional skills. However, neuroplasticity should not be presented as a cure or as evidence that damaged myelin will automatically regenerate. The current evidence supports rehabilitation as an important part of comprehensive MS care, while research continues to determine which approaches produce the most durable improvements.

Living With MS and Protecting Cognitive Health

Long-term management involves more than medication. Sleep, physical activity, mood, fatigue, pain and cognitive demands can all influence how well someone functions from day to day. A practical cognitive-wellness approach may include:

• Breaking complicated tasks into smaller steps
• Using calendars, reminders and written routines
• Reducing unnecessary multitasking
• Scheduling demanding activities during periods of better energy
• Maintaining appropriate physical activity with professional guidance
• Addressing sleep problems and persistent fatigue
• Discussing new or worsening cognitive symptoms with a healthcare professional
• Monitoring changes over time rather than relying on memory alone

Exercise deserves particular attention. A 2023 meta-analysis of 21 studies found a small but statistically significant overall improvement in cognitive function following exercise interventions in people with MS, including an effect on memory. However, the evidence remains heterogeneous, so exercise should be individualized rather than treated as a universal prescription.

Recent Research Highlights

Research is increasingly moving beyond the traditional focus on relapses and visible lesions toward progression, neuroaxonal injury, cognition and individualized monitoring.

One promising area is blood neurofilament light chain (NfL), a protein released when nerve fibres are damaged. A 2026 systematic review and meta-analysis combined 68 studies involving 19,159 participants and found significantly higher blood NfL levels in people with MS than in controls. Levels were also elevated across major MS subtypes. The findings support NfL as a promising biomarker, although researchers emphasize that clinical thresholds and interpretation still require refinement.  Another major development is the growing interest in treatments that target mechanisms associated with progression that may continue even without obvious relapses. The HERCULES results with Tolebrutinib provide important proof-of-concept evidence in non-relapsing SPMS, although safety monitoring remains crucial.

Recent Clinical Studies & Surveys

Recent research also highlights the importance of rehabilitation. A 2026 systematic review examined cognitive rehabilitation studies published from 2016–2024. From 10,460 initially identified records, 67 studies with original data were included after screening. The review found growing evidence for cognitive rehabilitation but also emphasized the need for stronger long-term studies that demonstrate whether improvements transfer into everyday functioning.

A 2024 systematic review of exercise-based telerehabilitation included 10 studies and found the approach generally feasible and safe, although effectiveness varied and adherence ranged from 38% to 100%. This is particularly relevant to people who face mobility, fatigue or geographic barriers to attending rehabilitation centres.

Real-World Perspective

MS demonstrates why brain health cannot be judged from one symptom or even from one test. Someone may walk relatively well while struggling with mental fatigue. Another person may experience obvious mobility difficulties while maintaining strong cognitive abilities. A third may have MRI changes without noticeable symptoms.

This variation reinforces the importance of longitudinal monitoring and individualized care. Understanding how symptoms, cognition, function and disease activity change over time can provide a more meaningful picture than a single snapshot.

Key Takeaways

• MS is an immune-mediated neurological disease that can damage myelin, axons and other nervous-system structures.
• Disrupted nerve signalling can affect vision, movement, sensation, balance, energy and cognition.
• MS does not follow one predictable pattern; relapsing and progressive forms can behave differently.
• Cognitive changes may involve processing speed, attention, memory, learning and executive function.
• Fatigue, sleep, mood and pain can also influence cognitive performance.
• Diagnosis requires a combination of clinical assessment, MRI and sometimes cerebrospinal-fluid or evoked-potential testing.
• Disease-modifying therapies can reduce disease activity and, for some forms of MS, slow disability accumulation.
• Rehabilitation can address physical, occupational, communication and cognitive difficulties.
• Exercise and cognitive rehabilitation are active areas of research, but individual programmes should be appropriately tailored.
• Blood NfL is emerging as a potentially useful biomarker, but it is not yet a standalone diagnostic test.
• Recent trials suggest that targeting mechanisms involved in progressive disability may become increasingly important.
• Long-term cognitive and functional monitoring can complement not replace, professional neurological care.

FAQ (Frequently Asked Questions)

1. What exactly happens to the brain in MS?
   The immune system mistakenly attacks components of the central nervous system, particularly myelin. Inflammation and damage can disrupt nerve signalling and may also affect axons and nerve cells.

2. Can MS affect memory?
   Yes. Some people experience changes involving memory, attention, learning, processing speed or executive function. The severity varies considerably.

3. Does MS always cause physical disability?
   No. MS affects people very differently. Some experience relatively mild symptoms, while others develop significant disability over time.

4. Is MS hereditary?
   MS has a genetic component, but it is not a straightforward inherited disease. Having a close relative with MS increases risk without determining that someone will develop it.

5. Is there a cure for multiple sclerosis?
   There is currently no cure, but treatments can reduce disease activity, manage symptoms and, in appropriate cases, slow disability progression. As of June 2026, Tolebrutinib is marketed in the EU under the brand name Cenrifki and has been approved for adults with secondary progressive MS without relapses in the previous two years.

6. Can exercise help cognitive function in MS?
   Research suggests that exercise may provide modest cognitive benefits, including possible improvements in memory, although findings vary between studies.

7. Can MS be diagnosed with an MRI alone?
   Usually not. MRI provides important evidence, but diagnosis involves the person’s symptoms, neurological examination, imaging and, when necessary, other investigations.

8. What is neurofilament light chain?
   NfL is a protein associated with nerve-fibre injury. Blood NfL is being investigated as a biomarker for disease activity and neuroaxonal damage in MS, but it is not a standalone diagnostic test.

9. What is the difference between a relapse and progression?
   A relapse is a period of new or worsening neurological symptoms, usually followed by some recovery. Progression refers to a more sustained accumulation of disability over time.

10. Can someone with MS have normal cognition & why is monitoring important in MS?
    Yes. Cognitive effects are variable, and not everyone with MS experiences significant cognitive impairment. MS can change over time, and symptoms do not always tell the whole story. Tracking cognition, function, symptoms and clinical measures can provide useful information for ongoing care.

DISCLAIMER: The content of this article is intended solely for general informational purposes and is not a substitute for professional medical consultation, diagnosis, or treatment. Always seek the advice of your doctor or another qualified healthcare professional regarding any medical concerns.